| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/01/2004 | EP1451173A2 Piperidines |
| 09/01/2004 | EP1451172A1 Therapeutic isoquinoline compounds |
| 09/01/2004 | EP1451169A1 Novel compounds for the treatment of cardiac arrhythmia, synthesis, and methods of use |
| 09/01/2004 | EP1451168A2 Paclitaxel solvates |
| 09/01/2004 | EP1451167A1 Phenylalkynes |
| 09/01/2004 | EP1451166A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof |
| 09/01/2004 | EP1451165A1 Substituted benzoxazoles and analogues as estrogenic agents |
| 09/01/2004 | EP1451164A2 Amide derivatives having improved solubility |
| 09/01/2004 | EP1451163A1 3-amido-1,2-benzoisoxazole derivatives, process for preparation, and use thereof |
| 09/01/2004 | EP1451162A1 Substituted diphenyl heterocycles useful for treating hcv infection |
| 09/01/2004 | EP1451161A1 Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands |
| 09/01/2004 | EP1451160A2 Pyrazole-amides and-sulfonamides |
| 09/01/2004 | EP1451159A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof |
| 09/01/2004 | EP1451158A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451157A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451156A1 4-aminoquinoline compounds |
| 09/01/2004 | EP1451154A2 Inhibitors of cytosolic phospholipase a2 |
| 09/01/2004 | EP1451153A1 Nk1 antagonists |
| 09/01/2004 | EP1451151A1 Hydroperylene derivatives |
| 09/01/2004 | EP1451146A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof |
| 09/01/2004 | EP1451145A1 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof |
| 09/01/2004 | EP1451144A1 Compositions for treating acne comprising phytandiol amine |
| 09/01/2004 | EP1451140A1 New process |
| 09/01/2004 | EP1451138A2 Methods of reversing and preventing cardiovascular pathologies |
| 09/01/2004 | EP1450867A1 Sterilizing tunnel for pharmaceutical containers |
| 09/01/2004 | EP1450862A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 09/01/2004 | EP1450859A2 Methods and compositions for the diagnosis of asthma |
| 09/01/2004 | EP1450858A2 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
| 09/01/2004 | EP1450856A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 09/01/2004 | EP1450853A1 Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions |
| 09/01/2004 | EP1450851A1 Treatment of congestive heart failure |
| 09/01/2004 | EP1450849A2 Methods of treating endometreosis |
| 09/01/2004 | EP1450847A2 Apo2 ligand/trail formulations |
| 09/01/2004 | EP1450844A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| 09/01/2004 | EP1450839A2 Method of treating estrogen responsive breast cancer |
| 09/01/2004 | EP1450835A2 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases |
| 09/01/2004 | EP1450826A1 Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium |
| 09/01/2004 | EP1450824A1 Pharmaceutical composition |
| 09/01/2004 | EP1450823A2 Biocidal mixture of 2-propenal-releasing polymer and isothiazolones |
| 09/01/2004 | EP1450822A2 Polymeric thiol-linked prodrugs |
| 09/01/2004 | EP1450821A1 Immunostimulatory oligodeoxynucleotides |
| 09/01/2004 | EP1450820A2 Method for treating or preventing inflammatory diseases |
| 09/01/2004 | EP1450819A1 Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection |
| 09/01/2004 | EP1450818A2 A method for treating inflammatory bowel disease |
| 09/01/2004 | EP1450817A1 Use of pregnane-diones or diols as neuropathic analgesic agents |
| 09/01/2004 | EP1450816A2 Method of treating disorder related to high cholesterol concentration |
| 09/01/2004 | EP1450815A2 Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
| 09/01/2004 | EP1450814A2 Methods of inhibiting metastases |
| 09/01/2004 | EP1450813A1 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| 09/01/2004 | EP1450812A2 Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| 09/01/2004 | EP1450811A2 2-aryl pyrrolopyrimidines for a1 and a3 receptors |
| 09/01/2004 | EP1450810A2 Xanthine oxidase inhibition |
| 09/01/2004 | EP1450809A2 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| 09/01/2004 | EP1450808A1 Quinazoline derivatives for the treatment of t cell mediated diseases |
| 09/01/2004 | EP1450807A1 Method of treating depression with delta receptor agonist compounds |
| 09/01/2004 | EP1450806A1 Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake |
| 09/01/2004 | EP1450805A1 Method for the treatment of overactive bladder |
| 09/01/2004 | EP1450804A1 Pharmaceutical formulations comprising an immune response modifier |
| 09/01/2004 | EP1450803A1 New uses for anti-malarial therapeutic agents |
| 09/01/2004 | EP1450802A2 Methods for the prevention or treatment of bacterial and fungal infections |
| 09/01/2004 | EP1450801A2 2-aminoquinoline compounds |
| 09/01/2004 | EP1450799A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 09/01/2004 | EP1450798A1 Use of an ascomycin for the treatment of blepharitis |
| 09/01/2004 | EP1450797A1 Benzothiazole derivatives |
| 09/01/2004 | EP1450796A1 Benzothiazole derivatives |
| 09/01/2004 | EP1450795A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
| 09/01/2004 | EP1450794A1 Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
| 09/01/2004 | EP1450793A2 Hypertonia treatment during the acute phase of a cerebrovascular accident |
| 09/01/2004 | EP1450792A1 Benzazole derivatives for the treatment of scleroderma |
| 09/01/2004 | EP1450791A1 Hydrazonopyrazole derivatives and their use as therapeutics |
| 09/01/2004 | EP1450789A1 STABLE, ACID, AQUEOUS SOLUTION CONTAINING a-LIPONIC ACID (DER IVATIVES), METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME |
| 09/01/2004 | EP1450788A1 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema |
| 09/01/2004 | EP1450787A2 Formulations and methods for treatment or amelioration of inflammatory conditions |
| 09/01/2004 | EP1450786A1 Isoflavone concentrate and method for production thereof |
| 09/01/2004 | EP1450785A1 Method of treating dermatoses using avermectin compound |
| 09/01/2004 | EP1450784A2 Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| 09/01/2004 | EP1450783A1 New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma |
| 09/01/2004 | EP1450782A1 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction |
| 09/01/2004 | EP1450781A1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 09/01/2004 | EP1450780A1 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation |
| 09/01/2004 | EP1450779A1 Method for treating autoimmune diseases |
| 09/01/2004 | EP1450778A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 09/01/2004 | EP1450777A1 Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity |
| 09/01/2004 | EP1450776A1 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof |
| 09/01/2004 | EP1450775A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
| 09/01/2004 | EP1450773A1 Transdermal therapeutic system provided with improved long-term carrying comfort |
| 09/01/2004 | EP1450772A1 Micronized film-forming powder comprising an active substance |
| 09/01/2004 | EP1450771A2 Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same |
| 09/01/2004 | EP1450770A2 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 09/01/2004 | EP1450769A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 09/01/2004 | EP1450768A1 Oral controlled release forms useful for reducing or preventing nicotine cravings |
| 09/01/2004 | EP1450767A1 Micropherules containing a pleuromutilin derivative |
| 09/01/2004 | EP1450762A1 Novel formulation |
| 09/01/2004 | EP1450760A2 Itch-relieving cosmetic and dermatological preparations |
| 09/01/2004 | EP1450756A1 Surfactant-containing cosmetic cleaning emulsions |
| 09/01/2004 | EP1450753A1 Antimicrobial composition comprising soy oil, rice bran oil and jojoba oil |
| 09/01/2004 | EP1450751A2 Nanoparticle delivery vehicle |
| 09/01/2004 | EP1450750A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase |
| 09/01/2004 | EP1450739A1 Hydrating nasal gel and applicator |
| 09/01/2004 | EP1450629A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof |